PinealonWhat the studies show

The most cited paper is from 2011 in Rejuvenation Research. The group grew cells in culture, exposed them to oxidative stress, and found that cells pre-treated with pinealon had lower levels of reactive oxygen species, less cell death, and a larger share of cells dividing than among untreated cells ². The authors read this as a protective, pro-proliferative effect. A 2007 paper from the same institute had already reported antioxidant activity for several of these pineal-derived peptides in test-tube assays ³. In 2014 the group reported that pinealon and related tripeptides increased the amount of serotonin produced in cultured cells from rat brain cortex ⁴.

All of this is in dishes. A cell-culture result tells you a molecule can do something to a cell when it is placed directly on it; it does not tell you the molecule reaches that cell in a living animal, or what happens when it does.

The one animal study that stands out gave pinealon to pregnant rats whose homocysteine had been artificially raised, a condition that damages the developing brain, and reported that the offspring had better spatial learning and less oxidative damage in brain tissue than the offspring of untreated mothers ⁵. It is a single study, with small groups, from the same institute, and it has not been repeated.

The group's explanation for how a three-amino-acid peptide could do anything is unusual. In a 2013 paper they proposed that these short peptides pass through the cell and nuclear membranes and settle into the groove of the DNA double helix at particular sequences, nudging the genes nearby on or off; the evidence was computer modelling of the peptide-to-DNA fit, plus experiments in which the peptides changed gene expression in cultured cells ¹. It is an interesting hypothesis. It has not been tested by anyone outside the institute, and the usual view in peptide chemistry is that a chain this short has no stable shape of its own, which makes specific DNA recognition hard to picture.

There is no published, placebo-controlled trial of pinealon in people in the PubMed-indexed literature, and no pharmacokinetic study showing that a three-amino-acid chain survives digestion and reaches the brain intact; the default expectation for a peptide this small is that the gut breaks it into its component amino acids, which are the same amino acids found in any protein meal. Every study above comes from one laboratory, the one that designed the molecule and holds the patents. That does not make the findings wrong, but it does mean nobody has checked them. In short: the evidence base is small, comes from one source, and stops at cells and rats.